隐匿性原发，版本 3.2014.
Occult primary, version 3.2014.
机构信息
From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Center Alliance; Massachusetts General Hospital Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Huntsman Cancer Institute at the University of Utah; University of Alabama at Birmingham Comprehensive Cancer Center; Roswell Park Cancer Institute; The University of Texas MD Anderson Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Memorial Sloan Kettering Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; and National Comprehensive Cancer Network.
出版信息
J Natl Compr Canc Netw. 2014 Jul;12(7):969-74. doi: 10.6004/jnccn.2014.0093.
The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.
NCCN 隐匿性原发肿瘤指南为隐匿性原发肿瘤（不明原发灶癌）患者的评估、检查、管理和随访提供了推荐意见。这些 NCCN 指南要点总结了 2014 年 NCCN 隐匿性原发肿瘤专家组会议的主要讨论点。专家组讨论了用于确定组织起源的基因表达谱（GEP），并得出结论，尽管 GEP 具有诊断益处，但尚未证明其具有临床益处。专家组建议不将 GEP 作为标准管理，但 20%的专家组认为 GEP 的诊断益处值得常规使用。此外，专家组还讨论了检测可操作突变（如 ALK）以帮助指导治疗选择，但拒绝添加此推荐意见。
Zotero 插件